These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19776093)

  • 1. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.
    Bielekova B; Richert N; Howard T; Packer AN; Blevins G; Ohayon J; McFarland HF; Stürzebecher CS; Martin R
    Mult Scler; 2009 Oct; 15(10):1206-14. PubMed ID: 19776093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis.
    Kraft P; Schwarz T; Göb E; Heydenreich N; Brede M; Meuth SG; Kleinschnitz C
    Exp Neurol; 2013 Sep; 247():80-90. PubMed ID: 23570902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
    Sommer N; Löschmann PA; Northoff GH; Weller M; Steinbrecher A; Steinbach JP; Lichtenfels R; Meyermann R; Riethmüller A; Fontana A
    Nat Med; 1995 Mar; 1(3):244-8. PubMed ID: 7585041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system.
    Abbas N; Zou LP; Pelidou SH; Winblad B; Zhu J
    Autoimmunity; 2000 Sep; 32(2):93-9. PubMed ID: 11078155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
    Moore CS; Earl N; Frenette R; Styhler A; Mancini JA; Nicholson DW; Hebb AL; Owens T; Robertson GS
    J Pharmacol Exp Ther; 2006 Oct; 319(1):63-72. PubMed ID: 16809479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
    Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.
    Paintlia AS; Paintlia MK; Singh I; Skoff RB; Singh AK
    Glia; 2009 Jan; 57(2):182-93. PubMed ID: 18720408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
    Sommer N; Martin R; McFarland HF; Quigley L; Cannella B; Raine CS; Scott DE; Löschmann PA; Racke MK
    J Neuroimmunol; 1997 Oct; 79(1):54-61. PubMed ID: 9357447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
    Folcik VA; Smith T; O'Bryant S; Kawczak JA; Zhu B; Sakurai H; Kajiwara A; Staddon JM; Glabinski A; Chernosky AL; Tani M; Johnson JM; Tuohy VK; Rubin LL; Ransohoff RM
    J Neuroimmunol; 1999 Jun; 97(1-2):119-28. PubMed ID: 10408965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats.
    Laemont KD; Schaefer CJ; Juneau PL; Schrier DJ
    Int J Immunopharmacol; 1999 Nov; 21(11):711-25. PubMed ID: 10576617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates aspirin-induced gastric mucosal injury in rats.
    Odashima M; Otaka M; Jin M; Komatsu K; Konishi N; Wada I; Horikawa Y; Matsuhashi T; Ohba R; Oyake J; Hatakeyama N; Watanabe S
    Dig Dis Sci; 2005 Jun; 50(6):1097-102. PubMed ID: 15986861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.
    Yang L; Calingasan NY; Lorenzo BJ; Beal MF
    Exp Neurol; 2008 May; 211(1):311-4. PubMed ID: 18328479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
    Harada D; Tsukumo Y; Takashima Y; Manabe H
    Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.
    González-García C; Bravo B; Ballester A; Gómez-Pérez R; Eguiluz C; Redondo M; Martínez A; Gil C; Ballester S
    Br J Pharmacol; 2013 Oct; 170(3):602-13. PubMed ID: 23869659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
    Sakura M; Masuda H; Matsuoka Y; Yokoyama M; Kawakami S; Kihara K
    BJU Int; 2009 Jan; 103(2):264-9. PubMed ID: 18710439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats].
    Nakamura C; Otaka M; Odashima M; Watanabe S
    Nihon Rinsho; 2004 Mar; 62(3):449-54. PubMed ID: 15038085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
    Jung S; Zielasek J; Köllner G; Donhauser T; Toyka K; Hartung HP
    J Neuroimmunol; 1996 Aug; 68(1-2):1-11. PubMed ID: 8784254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: TNF revisited, with promise.
    Raine CS
    Nat Med; 1995 Mar; 1(3):211-4. PubMed ID: 7585035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.